- Home
- MNPR vs NWTN Comparison
MNPR vs NWTN Comparison
Compare MNPR & NWTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- NWTN
- Stock Information
- Founded
- MNPR 2014
- NWTN 2016
- Country
- MNPR United States
- NWTN United Arab Emirates
- Employees
- MNPR N/A
- NWTN N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- NWTN Auto Manufacturing
- Sector
- MNPR Health Care
- NWTN Consumer Discretionary
- Exchange
- MNPR Nasdaq
- NWTN Nasdaq
- Market Cap
- MNPR 244.1M
- NWTN N/A
- IPO Year
- MNPR 2019
- NWTN N/A
- Fundamental
- Price
- MNPR $40.33
- NWTN $0.40
- Analyst Decision
- MNPR Strong Buy
- NWTN
- Analyst Count
- MNPR 5
- NWTN 0
- Target Price
- MNPR $49.60
- NWTN N/A
- AVG Volume (30 Days)
- MNPR 30.6K
- NWTN 332.0K
- Earning Date
- MNPR 05-08-2025
- NWTN 01-01-0001
- Dividend Yield
- MNPR N/A
- NWTN N/A
- EPS Growth
- MNPR N/A
- NWTN N/A
- EPS
- MNPR N/A
- NWTN N/A
- Revenue
- MNPR N/A
- NWTN $583,000.00
- Revenue This Year
- MNPR $34.06
- NWTN N/A
- Revenue Next Year
- MNPR N/A
- NWTN N/A
- P/E Ratio
- MNPR N/A
- NWTN N/A
- Revenue Growth
- MNPR N/A
- NWTN N/A
- 52 Week Low
- MNPR $1.72
- NWTN $0.35
- 52 Week High
- MNPR $54.30
- NWTN $8.74
- Technical
- Relative Strength Index (RSI)
- MNPR 56.65
- NWTN 36.50
- Support Level
- MNPR $36.80
- NWTN $0.40
- Resistance Level
- MNPR $43.00
- NWTN $0.44
- Average True Range (ATR)
- MNPR 5.32
- NWTN 0.06
- MACD
- MNPR 0.94
- NWTN 0.00
- Stochastic Oscillator
- MNPR 63.41
- NWTN 20.52
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.